Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial (2016)

Peer-Reviewed Study · Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ, Schelter BO, Davis CS, Staff RT, Bracoud L, Shamsi K, Storey JMD, Harrington CR, Wischik CM · November 16, 2016

Gauthier S et al., 2016-11-16: Second C14 row on the same paper: the authors themselves record that the 4 mg 'control' dose behaved like an active drug, that there was no dose-response between 75 and 125 mg twice daily, and that the trial was not designed to test the monotherapy comparison that later publicity rested on.

The unexpected benefit noted with the 4 mg dose delivered as monotherapy compared with add-on has made simple comparisons according to Alzheimer’s disease treatment status uninformative, and there were no differences by dose within monotherapy or add-on groups.

Discussion, limitations paragraph

Gauthier S et al., 2016-11-16: Second C14 row on the same paper: the authors themselves record that the 4 mg 'control' dose behaved like an active drug, that there was no dose-response between 75 and 125 mg twice daily, and that the trial was not designed to test the monotherapy comparison that later publicity rested on. This is the placebo-arm explanation for the negative result and simultaneously the weakness of the later post-hoc claims: the trial had no true placebo. Screening of the same discussion also yields the authors' statement that 'The few patients taking LMTM as monotherapy raises the possibility that the benefit noted in this group was a chance finding.' Registered NCT01689246 / EU CTR 2012-002866-11. Also filed as MTH-062, MTF-04, MTC-005, MTC-040, MTK-17, MTC-033, MTC-074, MTR-031, MTP-22 (claims C1, C11, C12, C14, C3, C4, C5, C6, C9). Study type: randomized trial.